Development of small RNA delivery systems for lung cancer therapy

International Journal of Molecular Sciences

Volumn 16, Issue 3, 2015, Pages 5254-5270

  Fujita, Yu ^a,b   Kuwano, Kazuyoshi ^b   Ochiya, Takahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug delivery system; Lung cancer; MiRNA; RNAi; SiRNA

Indexed keywords

MESSENGER RNA; SMALL INTERFERING RNA; EPHRIN RECEPTOR A2; NANOPARTICLE; PROTEIN KINASE C; PROTEIN KINASE N; RAS PROTEIN; RIBONUCLEOTIDE REDUCTASE;

CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; LUNG CANCER; NONHUMAN; NUCLEOTIDE SEQUENCE; QUANTITATIVE ASSAY; REVIEW; RNA INTERFERENCE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; GENETICS; LUNG NEOPLASMS; METABOLISM;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LUNG NEOPLASMS; NANOPARTICLES; PROTEIN KINASE C; RAS PROTEINS; RECEPTOR, EPHA2; RIBONUCLEOTIDE REDUCTASES; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84925881823     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16035254     Document Type: Review

References (86)

1. Zamore, P.D.; Tuschl, T.; Sharp, P.A.; Bartel, D.P. RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000, 101, 25–33.
2. Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391, 806–811.
3. Elbashir, S.M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411, 494–498.
4. Bernstein, E.; Caudy, A.A.; Hammond, S.M.; Hannon, G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001, 409, 363–366.
5. Aagaard, L.; Rossi, J.J. RNAi therapeutics: Principles, prospects and challenges. Adv. Drug Deliv. Rev. 2007, 59, 75–86.
6. De Fougerolles, A.; Vornlocher, H.P.; Maraganore, J.; Lieberman, J. Interfering with disease: A progress report on siRNA-based therapeutics. Nat. Rev. Drug Deliv. 2007, 6, 443–453.
7. Check, E. A crucial test. Nat. Med. 2005, 11, 243–244.
8. DeVincenzo, J.; Cehelsky, J.E.; Alvarez, R.; Elbashir, S.; Harborth, J.; Toudjarska, I.; Nechev, L.; Murugaiah, V.; van Vliet, A.; Vaishnaw, A.K, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antivir. Res. 2008, 77, 225–231.
9. Boudreau, R.L.; Martins, I.; Davidson, B.L. Artificial microRNAs as siRNA shuttles: Improved safety as compared to shRNAs in vitro and in vivo. Mol. Ther. 2009, 17, 169–175.
10. Burchard, J.; Jackson, A.L.; Malkov, V.; Needham, R.H.; Tan, Y.; Bartz, S.R.; Dai, H.; Sachs, A.B.; Linsley, P.S. MicroRNA-like off-target transcript regulation by siRNAs is species specific. RNA 2009, 15, 308–315.
11. De Veer, M.J.; Sledz, C.A.; Williams, B.R. Detection of foreign RNA: Implications for RNAi. Immunol. Cell Biol. 2005, 83, 224–228.
12. Winter, J.; Jung, S.; Keller, S.; Gregory, R.I.; Diederichs, S. Many roads to maturity: MicroRNA biogenesis pathways and their regulation. Nat. Cell Biol. 2009, 11, 228–234.
13. Croce, C.M, Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10, 704–714.
14. Esquela-Kerscher, A.; Slack, F.J. Oncomirs—MicroRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6, 259–269.
15. Pasquinelli, A.E.; Hunter, S.; Bracht, J. MicroRNAs: A developing story. Curr. Opin. Genet. Dev. 2005, 15, 200–205.
16. Ramalingam, S.S.; Owonikoko, T.K.; Khuri, F.R. Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J. Clin. 2011, 61, 91–112.
17. Pao, W.; Girard, N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011, 12, 175–180.
18. Turrisi, A.T.; Sherman, C.A. The treatment of limited small cell lung cancer: A report of the progress made and future prospects. Eur. J. Cancer 2002, 38, 279–291.
19. Kleinman, M.E.; Yamada, K.; Takeda, A.; Chandrasekaran, V.; Nozaki, M.; Baffi, J.Z.; Albuquerque, R.J.; Yamasaki, S.; Itaya, M.; Pan, Y, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452, 591–597.
20. Fujita, Y.; Takeshita, F.; Mizutani, T.; Ohgi, T.; Kuwano, K.; Ochiya, T. A novel platform to enable inhaled naked RNAi medicine for lung cancer. Sci. Rep. 2013, 3, doi:10.1038/srep03325.
21. Davidson, B.L.; McCray, P.B., Jr. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 2011, 12, 329–340.
22. DeVincenzo, J.; Lambkin-Williams, R.; Wilkinson, T.; Cehelsky, J.; Nochur, S.; Walsh, E.; Meyers, R.; Gollob, J.; Vaishnaw, A. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl. Acad. Sci. USA 2010, 107, 8800–8805.
23. Bouchie, A. Companies in footrace to deliver RNAi. Nat. Biotechnol. 2012, 30, 1154–1157.
24. Fujita, Y.; Takeshita, F.; Kuwano, K.; Ochiya, T. RNAi therapeutic platforms for lung diseases. Pharmaceuticals 2013, 6, 223–250.
25. Davis, M.E.; Zuckerman, J.E.; Choi, C.H.; Seligson, D.; Tolcher, A.; Alabi, C.A.; Yen, Y.; Heidel, J.D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464, 1067–1070.
26. Landen, C.N., Jr.; Chavez-Reyes, A.; Bucana, C.; Schmandt, R.; Deavers, M.T.; Lopez-Berestein, G.; Sood, A.K. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005, 65, 6910–6918.
27. Hama, S.; Arata, M.; Nakamura, I.; Kasetani, T.; Itakura, S.; Tsuchiya, H.; Yoshiki, T.; Kogure, K. Prevention of tumor growth by needle-free jet injection of anti-C7orf24 siRNA. Cancer Gene Ther. 2012, 19, 553–557.
28. Shim, G.; Choi, H.W.; Lee, S.; Choi, J.; Yu, Y.H.; Park, D.E.; Choi, Y.; Kim, C.W.; Oh, Y.K. Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes. Mol. Ther. 2013, 21, 816–824.
29. Fehring, V.; Schaeper, U.; Ahrens, K.; Santel, A.; Keil, O.; Eisermann, M.; Giese, K.; Kaufmann, J. Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC. Mol. Ther. 2014, 22, 811–820.
30. Dong, A.Q.; Kong, M.J.; Ma, Z.Y.; Qian, J.F.; Xu, X.H. Down-regulation of IGF-IR using small, interfering, hairpin RNA (siRNA) inhibits growth of human lung cancer cell line A549 in vitro and in nude mice. Cell Biol. Int. 2007, 31, 500–507.
31. Tian, H.; Liu, S.; Zhang, J.; Zhang, S.; Cheng, L.; Li, C.; Zhang, X.; Dail, L.; Fan, P.; Dai, L, et al. Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting Survivin. J. Biomed. Nanotechnol. 2012, 8, 633–641.
32. Kedinger, V.; Meulle, A.; Zounib, O.; Bonnet, M.E.; Gossart, J.B.; Benoit, E.; Messmer, M.; Shankaranarayanan, P.; Behr, J.P.; Erbacher, P, et al. Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases. BMC Cancer 2013, 13, doi:10.1186/1471-2407-13-338.
33. Bonnet, M.E.; Gossart, J.B.; Benoit, E.; Messmer, M.; Zounib, O.; Moreau, V.; Behr, J.P.; Lenne-Samuel, N.; Kedinger, V.; Meulle, A, et al. Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibition. J. Control. Release 2013, 170, 183–190.
34. Mainelis, G.; Seshadri, S.; Garbuzenko, O.B.; Han, T.; Wang, Z.; Minko, T. Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice. J. Aerosol Med. Pulm. Drug Deliv. 2013, 26, 345–354.
35. Taratula, O.; Garbuzenko, O.B.; Chen, A.M.; Minko, T. Innovative strategy for treatment of lung cancer: Targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug Targets 2011, 19, 900–914.
36. Okuda, T.; Kito, D.; Oiwa, A.; Fukushima, M.; Hira, D.; Okamoto, H. Gene silencing in a mouse lung metastasis model by an inhalable dry small interfering RNA powder prepared using the supercritical carbon dioxide technique. Biol. Pharm. Bull. 2013, 36, 1183–1191.
37. Li, J.; Yang, Y.; Huang, L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J. Control. Release 2012, 158, 108–114.
38. Han, J.; Wang, Q.; Zhang, Z.; Gong, T.; Sun, X. Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer. Small 2014, 10, 524–535.
39. Jiang, H.L.; Hong, S.H.; Kim, Y.K.; Islam, M.A.; Kim, H.J.; Choi, Y.J.; Nah, J.W.; Lee, K.H.; Han, K.W.; Chae, C, et al. Aerosol delivery of spermine-based poly(amino ester)/Akt1 shRNA complexes for lung cancer gene therapy. Int. J. Pharm. 2011, 420, 256–265.
40. Hong, S.H.; Kim, J.E.; Kim, Y.K.; Minai-Tehrani, A.; Shin, J.Y.; Kang, B.; Kim, H.J.; Cho, C.S.; Chae, C.; Jiang, H.L, et al. Suppression of lung cancer progression by biocompatible glycerol triacrylate-spermine-mediated delivery of shAkt1. Int. J. Nanomed. 2012, 7, 2293–2306.
41. Hong, S.H.; Minai-Tehrani, A.; Chang, S.H.; Jiang, H.L.; Lee, S.; Lee, A.Y.; Seo, H.W.; Chae, C.; Beck, G.R., Jr.; Cho, M.H. Knockdown of the sodium-dependent phosphate co-transporter 2b (NPT2b) suppresses lung tumorigenesis. PLoS One 2013, 8, e77121.
42. Yu, H.; Zou, Y.; Jiang, L.; Yin, Q.; He, X.; Chen, L.; Zhang, Z.; Gu, W.; Li, Y. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles. Biomaterials 2013, 34, 2738–2747.
43. Yang, Y.; Li, J.; Liu, F.; Huang, L. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol. Ther. 2012, 20, 609–615.
44. Das, J.; Das, S.; Paul, A.; Samadder, A.; Bhattacharyya, S.S.; Khuda-Bukhsh, A.R. Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo. Toxicol. Lett. 2014, 225, 454–466.
45. Conde, J.; Tian, F.; Hernandez, Y.; Bao, C.; Cui, D.; Janssen, K.P.; Ibarra, M.R.; Baptista, P.V.; Stoeger, T.; de la Fuente, J.M. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials 2013, 34, 7744–7753.
46. Zhang, Y.; Schwerbrock, N.M.; Rogers, A.B.; Kim, W.Y.; Huang, L. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol. Ther. 2013, 21, 1559–1569.
47. Dehousse, V.; Garbacki, N.; Colige, A.; Evrard, B. Development of pH-responsive nanocarriers using trimethylchitosans and methacrylic acid copolymer for siRNA delivery. Biomaterials 2010, 31, 1839–1849.
48. Fernandez, C.A.; Rice, K.G. Engineered nanoscaled polyplex gene delivery systems. Mol. Pharm. 2009, 6, 1277–1289.
49. Wu, Y.; Crawford, M.; Yu, B.; Mao, Y.; Nana-Sinkam, S.P.; Lee, L.J. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol. Pharm. 2011, 8, 1381–1389.
50. Xia, L.; Guan, W.; Wang, D.; Zhang, Y.S.; Zeng, L.L.; Li, Z.P.; Wang, G.; Yang, Z.Z. Killing effect of Ad5/F35-APE1 siRNA recombinant adenovirus in combination with hematoporphrphyrin derivative-mediated photodynamic therapy on human nonsmall cell lung cancer. BioMed Res. Int. 2013, 2013, doi:org/10.1155/2013/957913.
51. Gu, X.; Cun, Y.; Li, M.; Qing, Y.; Jin, F.; Zhong, Z.; Dai, N.; Qian, C.; Sui, J.; Wang, D. Human apurinic/apyrimidinic endonuclease siRNA inhibits the angiogenesis induced by X-ray irradiation in lung cancer cells. Int. J. Med. Sci. 2013, 10, 870–882.
52. Wang, X.M.; Cui, J.W.; Li, W.; Cai, L.; Song, W.; Wang, G.J. Silencing of the COPS3 gene by siRNA reduces proliferation of lung cancer cells most likely via induction of cell cycle arrest and apoptosis. Asian Pac. J. Cancer Prev. 2012, 13, 1043–1048.
53. Lian, Y.X.; Chen, R.; Xu, Y.H.; Peng, C.L.; Hu, H.C. Effect of protein-tyrosine phosphatase 4A3 by small interfering RNA on the proliferation of lung cancer. Gene 2012, 511, 169–176.
54. Liu, Y.; Yan, X.; Liu, N.; Zhou, J.; Liu, J.; Pang, H.; Cao, J.; Liu, Y.; Wang, Y.; Liu, L, et al. Lentivirus-delivered ZEB-1 small interfering RNA inhibits lung adenocarcinoma cell growth in vitro and in vivo. J. Cancer Res. Clin. Oncol. 2012, 138, 1329–1338.
55. Caino, M.C.; Lopez-Haber, C.; Kim, J.; Mochly-Rosen, D.; Kazanietz, M.G. Proteins kinase Cvarepsilon is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes. Oncogene 2012, 31, 2593–2600.
56. Wang, C.; Ding, C.; Kong, M.; Dong, A.; Qian, J.; Jiang, D.; Shen, Z. Tumor-targeting magnetic lipoplex delivery of short hairpin RNA suppresses IGF-1R overexpression of lung adenocarcinoma A549 cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 2011, 410, 537–542.
57. Vasudevan, S.; Tong, Y.; Steitz, J.A. Switching from repression to activation: MicroRNAs can up-regulate translation. Science 2007, 318, 1931–1934.
58. Bruno, I.G.; Karam, R.; Huang, L.; Bhardwaj, A.; Lou, C.H.; Shum, E.Y.; Song, H.W.; Corbett, M.A.; Gifford, W.D.; Gecz, J, et al. Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay. Mol. Cell 2011, 42, 500–510.
59. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with “antagomirs”. Nature 2005, 438, 685–689.
60. Misso, G.; di Martino, M.T.; de Rosa, G.; Farooqi, A.A.; Lombardi, A.; Campani, V.; Zarone, M.R.; Gulla, A.; Tagliaferri, P.; Tassone, P, et al. MiR-34: A new weapon against cancer? Mol. Ther. Nucleic Acids 2014, 3, doi:10.1038/mtna.2014.47.
61. Trang, P.; Wiggins, J.F.; Daige, C.L.; Cho, C.; Omotola, M.; Brown, D.; Weidhaas, J.B.; Bader, A.G.; Slack, F.J. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 2011, 19, 1116–1122.
62. Yanaihara, N.; Caplen, N.; Bowman, E.; Seike, M.; Kumamoto, K.; Yi, M.; Stephens, R.M.; Okamoto, A.; Yokota, J.; Tanaka, T, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9, 189–198.
63. Takamizawa, J.; Konishi, H.; Yanagisawa, K.; Tomida, S.; Osada, H.; Endoh, H.; Harano, T.; Yatabe, Y.; Nagino, M.; Nimura, Y, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64, 3753–3756.
64. Johnson, C.D.; Esquela-Kerscher, A.; Stefani, G.; Byrom, M.; Kelnar, K.; Ovcharenko, D.; Wilson, M.; Wang, X.; Shelton, J.; Shingara, J, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007, 67, 7713–7722.
65. Kumar, M.S.; Erkeland, S.J.; Pester, R.E.; Chen, C.Y.; Ebert, M.S.; Sharp, P.A.; Jacks, T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. USA 2008, 105, 3903–3908.
66. He, X.Y.; Chen, J.X.; Zhang, Z.; Li, C.L.; Peng, Q.L.; Peng, H.M. The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice. J. Cancer Res. Clin. Oncol. 2010, 136, 1023–1028.
67. Esquela-Kerscher, A.; Trang, P.; Wiggins, J.F.; Patrawala, L.; Cheng, A.; Ford, L.; Weidhaas, J.B.; Brown, D.; Bader, A.G.; Slack, F.J. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008, 7, 759–764.
68. Trang, P.; Medina, P.P.; Wiggins, J.F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Homer, R.; Brown, D.; Bader, A.G.; Weidhaas, J.B, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010, 29, 1580–1587.
69. Rai, K.; Takigawa, N.; Ito, S.; Kashihara, H.; Ichihara, E.; Yasuda, T.; Shimizu, K.; Tanimoto, M.; Kiura, K. Liposomal delivery of microRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol. Cancer Ther. 2011, 10, 1720–1727.
70. Wu, Y.; Crawford, M.; Mao, Y.; Lee, R.J.; Davis, I.C.; Elton, T.S.; Lee, L.J.; Nana-Sinkam, S.P. Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer. Mol. Ther. Nucleic Acids 2013, 2, doi:10.1038/mtna.2013.14.
71. Wiggins, J.F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Patrawala, L.; Brown, D.; Bader, A.G. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010, 70, 5923–5930.
72. Chiou, G.Y.; Cherng, J.Y.; Hsu, H.S.; Wang, M.L.; Tsai, C.M.; Lu, K.H.; Chien, Y.; Hung, S.C.; Chen, Y.W.; Wong, C.I, et al. Cationic polyurethanes-short branch PEI-mediated delivery of mirR145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J. Control. Release 2012, 159, 240–250.
73. Li, Y.J.; Zhang, Y.X.; Wang, P.Y.; Chi, Y.L.; Zhang, C.; Ma, Y.; Lv, C.J.; Xie, S.Y. Regression of A549 lung cancer tumors by anti-miR-150 vector. Oncol. Rep. 2012, 27, 129–134.
74. Cortez, M.A.; Valdecanas, D.; Zhang, X.; Zhan, Y.; Bhardwaj, V.; Calin, G.A.; Komaki, R.; Giri, D.K.; Quini, C.C.; Wolfe, T, et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol. Ther. 2014, 22, 1494–1503.
75. Fortunato, O.; Boeri, M.; Verri, C.; Moro, M.; Sozzi, G. Therapeutic use of microRNAs in lung cancer. BioMed Res. Int. 2014, doi:org/10.1155/2014/756975.
76. Burnett, J.C.; Rossi, J.J. RNA-based therapeutics: Current progress and future prospects. Chem. Biol. 2012, 19, 60–71.
77. Merkel, O.M.; Rubinstein, I.; Kissel, T. siRNA delivery to the lung: What’s new? Adv. Drug Deliv. Rev. 2014, 75, 112–128.
78. Jackson, A.L.; Bartz, S.R.; Schelter, J.; Kobayashi, S.V.; Burchard, J.; Mao, M.; Li, B.; Cavet, G.; Linsley, P.S. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 2003, 21, 635–637.
79. Bridge, A.J.; Pebernard, S.; Ducraux, A.; Nicoulaz, A.L.; Iggo, R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 2003, 34, 263–264.
80. Thomas, M.; Lu, J.J.; Chen, J.; Klibanov, A.M. Non-viral siRNA delivery to the lung. Adv. Drug Deliv. Rev. 2007, 59, 124–133.
81. Ahn, C.H.; Chae, S.Y.; Bae, Y.H.; Kim, S.W. Synthesis of biodegradable multi-block copolymers of poly(L-lysine) and poly(ethylene glycol) as a non-viral gene carrier. J. Control. Release 2004, 97, 567–574.
82. Bramson, J.L.; Bodner, C.A.; Graham, R.W. Activation of host antitumoral responses by cationic lipid/DNA complexes. Cancer Gene Ther. 2000, 7, 353–359.
83. Whitmore, M.; Li, S.; Huang, L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 1999, 6, 1867–1875.
84. Hamasaki, T.; Suzuki, H.; Shirohzu, H.; Matsumoto, T.; D’Alessandro-Gabazza, C.N.; Gil-Bernabe, P.; Boveda-Ruiz, D.; Naito, M.; Kobayashi, T.; Toda, M, et al. Efficacy of a novel class of RNA interference therapeutic agents. PLoS One 2012, 7, e42655.
85. Honma, K.; Iwao-Koizumi, K.; Takeshita, F.; Yamamoto, Y.; Yoshida, T.; Nishio, K.; Nagahara, S.; Kato, K.; Ochiya, T. RPN2 gene confers docetaxel resistance in breast cancer. Nat. Med. 2008, 14, 939–948.
86. Fujita, Y.; Yagishita, S.; Takeshita, F.; Yamamoto, Y.; Kuwano, K.; Ochiya, T. Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer. Oncotarget 2015, 6, 3335–3345.